Gopinath Nagaraj | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Gopinath Nagaraj | Pharmacology | Best Researcher Award

University of Madras | India

Dr. Gopinath Nagaraj is an accomplished biochemist and molecular biologist specializing in cardiovascular research, with a particular focus on elucidating the molecular mechanisms underlying cardiac hypertrophy and heart failure. He earned his Ph.D. in Biochemistry from the University of Madras under the mentorship of Prof. Elangovan Vellaichamy, where his doctoral research explored the intricate molecular pathways governing cardiac hypertrophy through both in vitro and in vivo models. His expertise encompasses a wide range of cellular and molecular biology techniques, including qPCR, Western blotting, ELISA, FACS analysis, and fluorescence microscopy, all of which he has skillfully applied to investigate receptor signaling mechanisms and molecular cardiology.Dr. Gopinath’s pioneering research centers on the natriuretic peptide receptor-A (NPR-A/GC-A) signaling pathway and its modulation in cardiovascular physiology. His studies provide valuable insights into how NPR-A expression, internalization, and trafficking dynamics regulate receptor function and contribute to cardiovascular homeostasis. Through his innovative integration of experimental and computational methods—such as molecular docking and receptor trafficking assays—he has advanced understanding of how natural compounds like curcumin modulate receptor function and restore cellular signaling in stress-induced cardiac hypertrophy and inflammation models. This approach bridges receptor biology with natural product pharmacology, opening new therapeutic possibilities for cardiovascular disease management.His notable publications include Triiodo-L-thyronine Downregulates Npr1 Gene Transcription in H9c2 Cells: Involvement of β-AR-ROS Signaling published in Endocrine; C-Type Natriuretic Peptide Induces Cell Death and Sensitizes the Effect of Cisplatin in Human Non-Small Cell Lung Cancer Cells in International Journal of Peptide Research and Therapeutics; CNP Inhibits T3-Induced Hypertrophic Growth in H9c2 Cells: Impact of HDAC Inhibitor in Archives of Biochemistry and Biophysics; Curcumin with ANP Treatment Enhances the Internalization and Trafficking of NPR-A Mediated Signaling Pathway in Tissue and Cell; and Epigenetic Modulation of Natriuretic Peptide Receptor Signaling by HDAC Inhibitors in Thyroxine-Induced Cardiac Hypertrophy submitted to the European Journal of Pharmacology. Dr. Gopinath has contributed expert consultancy in receptor signaling and preclinical molecular evaluation for bioactive compounds, polymers, and nanoparticles with cardioprotective, anticancer, and anti-inflammatory properties. With multiple ongoing research projects, five publications in high-impact journals, and an h-index of three, he continues to strengthen the translational link between molecular cardiology and therapeutic innovation. His role as a reviewer for Discover Oncology further reflects his commitment to upholding scientific integrity and excellence in biomedical research. Through his innovative research, multidisciplinary collaborations, and translational insights, Dr. Gopinath exemplifies scientific dedication in advancing cardiovascular and molecular biosciences.

Profile: Google Scholar

Featured Publications

Elumalai, M., Nagaraj, G., Kasthuri, J., Vellaichamy, E., & Rajendiran, N. Evaluation of cytotoxic activity against A549 human lung cancer cells using green synthesized N-Cholyl D-Penicillamine encapsulated silver and gold nanoparticles. Inorganic Chemistry Communications, 153, 110834.

Baskaran, A., Elumalai, M., Nagaraj, G., Vellaichamy, E., & Rajendiran, N. Mucoadhesive and drug release of cholic acid-based thiomeric micelles and encapsulated silver and gold nanoparticles for anticancer studies. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 703, 135363.

Nagaraj, G., Dhanusu, S., Nachiappan, D. M., & Vellaichamy, E. C-type natriuretic peptide (CNP) induces cell death and sensitizes the effect of cisplatin in human non-small cell lung cancer cells (A549). International Journal of Peptide Research and Therapeutics, 28(4), 112.

Nagaraj, G., & Vellaichamy, E. Triiodo-L-thyronine (T3) downregulates Npr1 gene (coding for natriuretic peptide receptor-A) transcription in H9c2 cells: involvement of β-AR-ROS signaling. Endocrine, 85(3), 1075–1090.

Nagaraj, G., & Vellaichamy, E. CNP inhibits T3-induced hypertrophic growth in H9c2 cells: Impact of HDAC inhibitor. Archives of Biochemistry and Biophysics, 110648.

Elumalai, M., Nagaraj, G., Ramaraj, S. G., Vellaichamy, E., Tabata, H., & Rajendiran, N. NCPA-templated red-emitting gold nanoclusters: a turn-off-on fluorescent probe for rapid and selective detection of Cu²⁺ ions in live cells and evaluation of biological applications. Dalton Transactions (Cambridge, England: 2003).

Huachuan Zheng | Pharmacology | Best Innovation Award

Published on by Top Pharmaceutical

Prof. Dr. Huachuan Zheng | Pharmacology | Best Innovation Award

The First Affiliated Hospital of Jinzhou Medical University | China

Prof. Dr. Huachuan Zheng is a distinguished scholar, educator, and research leader whose pioneering work in oncology has significantly advanced the understanding of cancer biology and its clinical applications. With a strong academic foundation that began at China Medical University, where he earned his B.M., M.S., and M.D. degrees, followed by a Ph.D. in Pathology from the University of Toyama in Japan, Prof. Zheng has built a career dedicated to unraveling the molecular mechanisms underlying tumor development and progression. His postdoctoral fellowship at the Kanagawa Cancer Center in Japan further strengthened his expertise in cancer molecular pathology, setting the stage for a prolific academic and research journey.Throughout his career, Prof. Zheng has held several prestigious positions, including serving as the Director of Basic and Translational Cancer Laboratories, Central Laboratories, Experimental Animal Centers, and Cancer Experiment Centers at leading institutions such as the First Affiliated Hospital of Jinzhou Medical University and the Affiliated Hospital of Chengde Medical University. His leadership has extended beyond research to academic administration, where he has contributed as Secretary of the Party Committee and Executive Vice Dean at the Jinzhou Medical University Academy of Life Sciences. Currently, he serves as Director, Professor, and Doctoral Supervisor at the First Affiliated Hospital of Jinzhou Medical University, where he continues to guide innovative cancer research and mentor the next generation of scientists. Prof. Zheng’s research has focused on critical areas such as the molecular mechanisms driving malignant tumor initiation and metastasis, the carcinogenic pathways involving JC virus T antigen, cancer bioinformatics, and the development of spontaneous tumor transgenic animal models. Prof. Zheng leads cutting-edge research on malignant tumor initiation, metastasis, JC virus oncogenesis, cancer bioinformatics, and transgenic animal models. His prolific output includes 212 documents, 5,182 citations, and an h-index of 36, reflecting his global impact on cancer research and precision oncology. His groundbreaking work has not only contributed to the fundamental understanding of cancer biology but has also paved the way for translational applications in early diagnosis, targeted therapy, and personalized treatment approaches for various malignancies, including lung, digestive system, and gynecological cancers.

Profile: Scopus

Featured Publications

Author(s). (2025). RNF180 suppressed aggressiveness by degrading NOTCH1, TRIM24 and FOXC1, and chemoresistance by degrading ACC1 and ACLY in colorectal cancer. International Immunopharmacology.

Author(s). (2025). Effective synthesis of benzodiazepine sulfonamide-based MGAT2 inhibitors and evaluation of their antitumor activity. RSC Advances.

Author(s). (2025). Dkk3 inhibits the aggressiveness and mitigates chemoresistance through low lipid droplet formation in gastric cancer: A biomarker and gene therapy target. International Immunopharmacology.

Author(s). (2025). IFN-γ downregulates miR-4319 to enhance NLRC5 and MHC-I expression in MHC-I-deficient breast cancer cells. Cancer Biology and Therapy.

Author(s). (2025). RNF180 weakened the lipid droplet formation and subsequent chemoresistance by destabilizing ACC1 and ACLY in esophageal cancer. Frontiers in Pharmacology.

Author(s). (2025). Chaetoglobosin A induces apoptosis in T-24 human bladder cancer cells through oxidative stress and MAPK/PI3K-AKTmTOR pathway. PeerJ.

Author(s). (2024). The promoting effects of Grin2d expression in tumorigenesis and the aggressiveness of esophageal cancer. Histology and Histopathology.

Author(s). (2024). The antitumor and sorafenib-resistant reversal effects of ursolic acid on hepatocellular carcinoma via targeting ING5. International Journal of Biological Sciences.

Author(s). (2024). The oncogenic roles of GPR176 in ovarian cancer: A molecular target for aggressiveness and gene therapy. Journal of Obstetrics and Gynaecology.